Global Oncology Integrated Therapeutic Area Opportunity Review
MMC International is undertaking a Global Oncology Integrated Therapeutic Area/Disease Opportunity Review (GOIDOR) which will become a benchmark study that will be updated on an annual or bi-annual basis, depending on the section. Relationships have been, are and will be formalized with industry thought leaders and key opinion leaders to allow regular updates as well as ad hoc studies. Study sponsors will get special benefits versus companies that purchase the report after its release. The following are the countries that will be covered by this review:
North America United States Canada
Europe France Germany Italy Spain United Kingdom
Japan
Emerging Seven Brazil China India Indonesia Mexico Russia Turkey
The Global Oncology Integrated Therapeutic Area/Disease Opportunity Review is comprise of three independent but interrelated reports:
1. Global Oncology Commercial Environment Overview - 2011 Through 2020 2. Global Oncology Product Portfolio Review - 2011 Through 2020 3. Alternative Oncology Strategies - 2011 Through 2020
Sponsor presentations will be customized to focus on sponsor specific issues as well as the cancers and/or supportive care conditions of interest. Sponsors will receive early access to information and will get advanced review of the potential product in-licensing and/or company acquisition opportunities.
The following are links to the respective report brochures:
For more information, please contact your MMC representative, call Ed Valentine at 203-961-9352 or e-mail hime at: e.valentine@mmcint.com, or fill out the Contact Us request on the website.
